Comprehensive Immunogenomic Profiling of IDH1- / 2 -Altered Cholangiocarcinoma
JCO Precision Oncology · 2024
DOI: 10.1200/po.23.00544 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Shalini Makawita und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology & Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS.
Abstract (Originalsprache)
PURPOSE Isocitrate dehydrogenase ( IDH) 1/ 2 genomic alterations (GA) occur in 20% of intrahepatic cholangiocarcinoma (iCCA); however, the immunogenomic landscape of IDH1-/2-mutated iCCA is largely unknown. METHODS Comprehensive genomic profiling (CGP) was performed on 3,067 cases of advanced iCCA. Tumor mutational burden (TMB), PD-L1 expression (Dako 22C3), microsatellite instability (MSI), and genomic loss of heterozygosity (gLOH) as a surrogate marker for homologous recombination deficiency were examined. RNA sequencing of 73 patient samples was analyzed for differences in stromal/immune cell infiltration, immune marker expression, and T-cell inflammation. Tissue microarray arrays were subjected to multiplex immunohistochemistry and colocalization analysis in 100 surgical samples. Retrospective clinical data were collected for 501 patients with cholangiocarcinoma to examine median overall survival (mOS) in IDH1/2+ versus IDHwt. RESULTS Of 3,067 iCCA cases subjected to CGP, 426 (14%) were IDH1+ and 125 (4%) were IDH2+. IDH1 GA included R132C (69%) and R132L/G/S/H/F (16%/7%/4%/3%/
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology & Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX.
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Bioinformatics and Computational Biology, The University of Texas MD, Houston, TX.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Houston Methodist Research Institute, Houston, TX.
- Department of Pediatrics-Diabetes and Endocrinology, Baylor College of Medicine, Houston, TX.
ORCID-Profile: Shalini Makawita, Lawrence N Kwong, Zeyad Abouelfetouh, Anaemy Danner De Armas, Karthikeyan Murugesan, Natalie Danziger, Dean Pavlick, Jeffrey S Ross, Milind Javle
Förderung
- NLM NIH HHS
Zitieren
APA
Makawita, S., Lee, S., Kong, E., Kwong, L. N., Abouelfetouh, Z., Danner De Armas, A., Xiao, L., Murugesan, K., Danziger, N., Pavlick, D., Korkut, A., Ross, J. S., & Javle, M. (2024). Comprehensive Immunogenomic Profiling of IDH1- / 2 -Altered Cholangiocarcinoma. JCO Precision Oncology. https://doi.org/10.1200/po.23.00544
Vancouver
Makawita S, Lee S, Kong E, Kwong LN, Abouelfetouh Z, Danner De Armas A, et al. Comprehensive Immunogenomic Profiling of IDH1- / 2 -Altered Cholangiocarcinoma. JCO Precision Oncology. 2024. doi:10.1200/po.23.00544
BibTeX
@article{Makawita2024,
author = {Makawita, Shalini and Lee, Sunyoung and Kong, Elisabeth and Kwong, Lawrence N and Abouelfetouh, Zeyad and Danner De Armas, Anaemy and Xiao, Lianchun and Murugesan, Karthikeyan and Danziger, Natalie and Pavlick, Dean and Korkut, Anil and Ross, Jeffrey S and Javle, Milind},
title = {Comprehensive Immunogenomic Profiling of IDH1- / 2 -Altered Cholangiocarcinoma},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.23.00544}
}
EUVIMED